ストックスクリーナーアプリを入手
24.78
3.95%
-1.02
前日終値:
$25.80
開ける：
$25.79
24時間の取引高:
290.24K
Relative Volume:
0.35
時価総額：
$N/A
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-3.47%
1か月 パフォーマンス:
+12.08%
6か月 パフォーマンス:
+54.68%
1年 パフォーマンス:
+32.16%
1日の値動き範囲:
$24.72
$26.66
1週間の範囲:
$23.48
$28.14
52週間の値動き範囲:
$9.60
$28.44
Defiance Daily Target 2 X Long Lly Etf Stock (LLYX) Company Profile
LLYX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LLYX
Defiance Daily Target 2 X Long Lly Etf
|
24.78 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
342.40 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
694.07 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
697.08 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
271.79 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
626.65 | 124.43B | 0 | 0 | 0 | 0.00 |
Defiance Daily Target 2 X Long Lly Etf (LLYX) 最新ニュース
The 2X Long INTC (INTW) fund rose by 13.10% with a trading value of $111.98 million. - Sahm
Defiance Daily Target 2X Short LLY ETF (LLYZ) AI-Powered Stock Analysis - Meyka
Eli Lilly and Co’s significant oral weight-loss drug trial achieves new progress: Switching from injection to oral form effectively maintains weight loss results, with an application for market approval submitted to the FDA. - 富途牛牛
Market Chatter: Eli Lilly and Company to Reduce Prices of Its Diabetes, Weight-Loss Drugs in Canada by 20% or More - 富途牛牛
Market Chatter: Eli Lilly Could Get FDA Decision for Weight-Loss Pill Orforglipron by March 2026 - 富途牛牛
Best Stocks Under $50 Right Now - Benzinga
LLYZDefiance Daily Target 2X Short LLY ETF Earnings - Finviz
Defiance Daily Target 2X Long LMND ETF Holdings List (NASDAQ:LMNX) - MarketBeat
Sell on the Pop Prospects: October 15 Edition - ETF Database
Defiance Daily Target 2X Short LLY ETF (LLYZ) options chain - Yahoo
Defiance Daily Target 2X Short LLY ETF (LLYZ) latest stock news and headlines - Yahoo
Check out Defiance Daily Target 2X Short LLY ETF's stock price (LLYZ) in real time - CNBC
Leveraged ETFs: Single-Stock Surge - Seeking Alpha
Single-Stock Surge in Leveraged ETFs - ETF Database
Defiance Has A New ETF For High-Stakes Pharma Traders - Sahm
Defiance ETFs launches 2X short ETF on Eli Lilly - MSN
Tidal Trust IIDefiance Daily Target 2X Short LLY ETF - CMLviz
Largest borrow rate increases among liquid names - TipRanks
US launches from 28th August to 4th September, 2025 - ETF Express
Defiance Launches 2X Short ETF on Eli Lilly for Retail Investors - AInvest
Defiance’s LLYZ ETF: A Leveraged Bet Against Eli Lilly Amid Biopharma Sector Turbulence - AInvest
Attachment - GlobeNewswire
Defiance Launches LLYZ: The First 2X Short ETF for Eli Lilly - GlobeNewswire
Defiance Launches LLYZ: A New 2X Short ETF for Eli Lilly Investors - AInvest
Weekly ETF Industry News Recap | August 25August 29, 2025 - Trackinsight
Largest Borrow Rate Increases Among Liquid Stocks - AInvest
U.S. Stock ETF Tracking | Eli Lilly and Co's weight loss drug is expected to submit for FDA approval within the year, resulting in a more than 11% increase in the 2x long LLY ETF; international oil prices have fallen to nearly $60 per barrel, leading to o - 富途牛牛
Novo Nordisk Plunges 2.6% Amid Legal Storm and Rival Drug Data – What’s Next for NVO? - AInvest
Eli Lilly's LLY Surges 4.38% on Groundbreaking Obesity Drug Data – What's Next for the Pharma Giant? - AInvest
Best-Performing Leveraged ETFs of Last Week - Yahoo Finance
Big Tech Woes Power Surge in Inverse Single-Stock ETFs - Yahoo Finance
Novo Nordisk Surges 2.46% Amid Leadership Shift and Sector Volatility – What’s Fueling the Rally? - AInvest
Eli Lilly Surges 3.36% Amid UK Price Hike and AI-Driven Obesity Deal: What’s Fueling the Rally? - AInvest
Eli Lilly Surges 3% on Insider Buying and Regulatory Drama – What’s Next? - AInvest
Eli Lilly Soars on Insider Buying Amid Regulatory Storm: A 3% Rally Amid Legal and Trial Turmoil - AInvest
Eli Lilly Surges 2.48% Amid Regulatory Turmoil and Sector Volatility – What’s Fueling the Rally? - AInvest
Novo Nordisk Surges 4.7% Amid Obesity Drug Rivalry: Is This the New Benchmark? - AInvest
US ETF Tracker | Trump announces nomination of Stephen Moore for Federal Reserve governor, double-leveraged small gold miners index ETF rises nearly 3%, Eli Lilly and Co's new drug underperforms expectations, double-leveraged LLY ETF falls over 28 - 富途牛牛
Sarepta Soars 8.55% on Earnings & FDA Greenlight: Can This Biotech Rebound Sustain Momentum? - AInvest
NVO's 6.37% Surge: A Bullish Rebound Amid Earnings Volatility and Sector Shifts - AInvest
Defiance Launches QPUX: 2X Leveraged ETF on Pure Quantum Companies - Yahoo Finance
Eli Lilly Plummets 3% as Sector Turmoil and Rival Struggles Ignite Selling Frenzy - AInvest
U.S. Market Outlook | Equity Index Futures Rise, Super Micro Computer (SMCI.US) Falls Post-Earnings, Trump to Make Statement After Market Close - 富途牛牛
Leveraged Bearish Strategy ETF Surges 19%, Signals Dour Outlook for MSTR and Bitcoin - Yahoo Finance
Novo Nordisk Plunges 3.45%: Is This the Bottom or a Deeper Downtrend? - AInvest
Novo Nordisk Plunges 4.56%—Is This a Golden Entry Point or a Deepening Abyss? - AInvest
Novo Nordisk Plunges 5.7%—What’s Fueling the Crisis of Confidence? - AInvest
Novo Nordisk Shares Plunge, Drag Down Weight-Loss-Drug ETFs - Yahoo Finance
Novo Nordisk Plunges 21.19%—What’s Behind the Sudden Collapse? - AInvest
Form 485BPOS Tidal Trust II - StreetInsider
Defiance Launches JPX: The First 2X Leveraged ETF on JPM (JP Morgan) - FinancialContent
Defiance Daily Target 2 X Long Lly Etf (LLYX) 財務データ
Defiance Daily Target 2 X Long Lly Etf (LLYX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.64%
大文字化:
|
ボリューム (24 時間):